GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of …
GSK announces positive phase III results from ANCHOR trials for ...
Oct 14, 2024 · Depemokimab’s extended half-life, high potency and high binding affinity for IL-5 means it has the potential to provide sustained inhibition of broad inflammatory functions with …
Depemokimab accepted for review by the European Medicines Agency ... - GSK
Jan 28, 2025 · Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory …
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
GSK reports data from Phase III trials of severe asthma treatment
Sep 10, 2024 · UK-based pharmaceutical company GSK has announced results from two Phase III clinical trials of depemokimab in patients with severe asthma characterised by elevated …
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 …
GSK boasts win for depemokimab in asthma trials - Clinical Trials …
May 21, 2024 · GSK has announced positive data from two Phase III trials of its asthma candidate depemokimab. The pharma giant announced the drug met primary endpoints in both the …
GSK’s twice-yearly asthma drug clears two phase 3 trials
6 days ago · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly …
GSK's long-acting asthma drug halved attacks in phase 3
Sep 9, 2024 · GSK is continuing to tout depemokimab as one of its 12 potential blockbuster launches of the coming years, with the asthma drug expected to generate peak-year sales of 3 …
GSK’s Depemokimab Significantly Reduces Asthma Exacerbations
Sep 10, 2024 · Results from a pooled analysis of the Phase III SWIFT-1 and SWIFT-2 trials demonstrated that GSK’s depemokimab, a biologic targeting severe asthma with type 2 …